Suppr超能文献

采用质谱法评价双硫仑及其铜配合物在 A549 细胞中的积累。

Evaluation of the accumulation of disulfiram and its copper complex in A549 cells using mass spectrometry.

机构信息

Department of Chemistry,School of Science,Tianjin University,Tianjin, 300075,China; Department of Chemistry,Beijing Key Laboratory of Microanalytical Methods and Instrumentation,MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University,Beijing, 100084,China.

Department of Chemistry,Beijing Key Laboratory of Microanalytical Methods and Instrumentation,MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University,Beijing, 100084,China.

出版信息

Talanta. 2020 May 1;211:120732. doi: 10.1016/j.talanta.2020.120732. Epub 2020 Jan 9.

Abstract

The famous alcohol-aversion drug disulfiram (DSF) is a promising candidate for repurposing in cancer therapy, as indicated by many ongoing and completed clinical trials. Existing researches focus on demonstrating that the anti-cancer activity of DSF is enhanced by copper ions, or solving the problem that DSF is easily decomposed in the body to lose its activity. However, the metabolic kinetics of its ultimate anti-cancer metabolite DDC-Cu (bis-diethyldithiocarbamate-copper) in cells and how it exerts anti-cancer mechanisms remain unclear. In this work, mass spectrometric evaluation of the intracellular and extracellular accumulation of DSF and its copper complex DDC-Cu was performed. Combined with cytotoxicity assay, staining analysis and flow cytometry, we found that DDC-Cu could easily pass through the cell membrane of A549 cells, and accumulate intracellularly for a long time. This process can lead to cellular morphological changes, an increase in ROS content, cell cycle arrest in the G0/G1 phase and apoptosis. Besides, molecular cancer-relevant targets of DDC-Cu in cancer cells were further discussed. This work investigated the cytotoxic mechanism of DDC-Cu, which has important clinical significance for its application in cancer therapy.

摘要

著名的戒酒药物双硫仑(DSF)是癌症治疗再利用的有前途的候选药物,许多正在进行和已完成的临床试验都表明了这一点。现有研究集中于证明 DSF 的抗癌活性是通过铜离子增强的,或者解决 DSF 容易在体内分解失去活性的问题。然而,其最终抗癌代谢物 DDC-Cu(双二乙基二硫代氨基甲酸盐-铜)在细胞中的代谢动力学及其发挥抗癌机制仍不清楚。在这项工作中,对 DSF 及其铜复合物 DDC-Cu 的细胞内和细胞外积累进行了质谱评估。结合细胞毒性测定、染色分析和流式细胞术,我们发现 DDC-Cu 可以轻易地穿过 A549 细胞的细胞膜,并在细胞内长时间积累。这个过程会导致细胞形态发生变化,ROS 含量增加,细胞周期停滞在 G0/G1 期和细胞凋亡。此外,还进一步讨论了 DDC-Cu 在癌细胞中的分子癌症相关靶标。这项工作研究了 DDC-Cu 的细胞毒性机制,这对其在癌症治疗中的应用具有重要的临床意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验